Sign In
Linkedin Youtube
EN ES

Publications

Publication Type
Keywords
Publication Year

Weston Park Hospital, Sheffield, United Kingdom, University of LeedS, United Kingdom, AZURE (BIG 01/01) investigators. adjuvant treatment with zoledronic acid in stage II/II breast cancer. The AZURE trial (BIG 01/04)

Congress Communications
Author:
Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Davies C, Bell R.
Parent Trial:

AZURE

Cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial.

Congress Communications
Author:
Baselga J, Stemmer S, Pego A, Chan A, Goeminne J-C, Graas M-P, Kennedy J, Ciruelos Gil EM, Zubel A, Groos J, Kia U, Schneeweiss A.
Parent Trial:

BALI-1

The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1).

Congress Communications
Author:
Baselga J, Gomez P, Awada A, Greil R, Braga S, Climent MA, Wardley A, Zubel A, Groos J, Kaufman B.
Parent Trial:

BALI-1

Biomarker analysis of a phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole or placebo plus letrozole as neoadjuvant therapy for patients with estrogen receptor positive breast cancer

Congress Communications
Author:
Gardner H, Bandaru R, Barrett C, Calcaterra M, Crowell T, Decker J, Dixon M, Fisch R, Fuchs M, Gelb A, Hanoteau N, Jonat W, Lane H, Lebwohl D, Liu W-H, Molloy B, Pena C, Phillips P, Rheinhardt J, Rugo H, Salesky S, Steinseifer J, Stumm M, Tokaji E, Voelker F, Yarbrough G, Yateman N, Yu Y, Zuber E, Baselga J.
Parent Trial:

EVEROLIMUS / RAD-FEMARA

Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial

Article
Author:
Procter M, Suter TM, Azambuja E, Dafni U, Van Dooren V, Muehlbauer S, Climent MA, Jakesz R, Tsang-Wu Liu W, Toi M, Coombes C, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen D, Piccart-Gebhart MJ for the HERA trial study team.
Parent Trial:

HERA

Adjuvant chemotherapy prescription according to multidisciplinary team decision or the MINDACT protocol (microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy) (EORTC10041 BIG 3-04).

Congress Communications
Author:
Mitine C, Doneux A, Majois F, Samartzi V, Godart D, Neybuch Y, Petit B, Confente C, Beauduin M, Gérard R.
Parent Trial:

MINDACT

First results of the NEOALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER 2-positive primary breast cancer.

Congress Communications
Author:
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E, Gomez H, Dinh P, Fauria K, Van Dooren V, Paoletti P, Goldhirsch A, Chang T-W, Lang I, Untch M, Gelber RD, Piccart-Gebhart M.
Parent Trial:

NEOALTTO

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Article
Author:
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J.
Parent Trial:

NOAH

Management of hand-foot skin reaction (HFSR)/hand-foot syndrome (HFS) in SOLTI-0701: a double-blind, randomized phase IIb study comparing sorafenib (SOR) versus placebo (PL) in combination with capecitabine (CAP) in patients (PTS) with advanced breast cancer (BC).

Congress Communications
Author:
Gomez P, Roche HH, Costa F, Segalla J, Pinczowski H, Cabral Filho S, Ciruelos E, Van Eyll BM, Baselga J.
Parent Trial:

SOLTI-0701 SORAFENIB FASEII

Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (PTS) with HER2-negative locally advanced or metastatic breast cancer (BC).

Congress Communications
Author:
Gradishar WJ, Dalenc F, Kaklamani VG, Costa F, Sahoo TP, Segalla J, Lokanatha D, Pinczowski H, Raina V, Baselga J
Parent Trial:

SOLTI-0701 SORAFENIB FASEII
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  
X

En Grupo Solti utilizamos cookies, propias y de terceros, analíticas, publicitarias y de elaboración de perfiles, basadas en hábitos de navegación del usuario, para mejorar la calidad del servicio, medir la audiencia y ofrecerle publicidad que pueda ser de su interés. Puede obtener más información en nuestra Política de Cookies.

Entendemos que acepta el uso de cookies en caso de que siga navegando.

Puede gestionar las cookies y aceptarlas o rechazarlas en el Panel de Configuración.